ELRIG networking event

December 6th, 2017 / Events

“PROTACs – An exciting therapeutic modality”

Ubiquigent will be attending and presenting at the upcoming ELRIG networking event, organised in association with AstraZeneca

The event is free to attend and will be held at the Alderley Park Conference Centre on the 6th December 2017, 14:00 – 19:00. Register here

An event flyer containing full details of the event here: “PROTACs – An exciting therapeutic modality”

Proteolysis targeting chimeras (PROTACs) offer a novel alternative to traditional small molecules. They inhibit proteins by binding to their functional regions and by recruiting E3 ligases to target the protein for degradation through the cells natural ubiquitin/proteasome pathway. This event will focus on the recent developments in the field, provide an opportunity to learn about the types of protein complexes that are being considered as PROTAC targets and provide an introduction to those new to the field who are looking to start engaging with PROTACs within their own research. Informal presentations will be given by guest speakers followed by a networking session over food and drinks.

Confirmed speakers for this event are:

  • “PROTACs – Foundation and recent developments”
  • Thomas Hayhow (Medicinal Chemist, AstraZeneca)
  • “Understanding the role of class-I HDAC complexes: a precise method of targeting deacetylase activity in cells”
  • Shaun Cowley (Chair of Molecular Biology, University of Leicester)
  • “Small Molecule Designer Libraries for Mutant p53 Rescue”
  • John Spencer (Professor of Bio-organic Chemistry, University of Sussex)
  • An integrated chemistry and assay platform enabling client ubiquitin-system targeted drug discovery and towards supporting the development of PROTAC-based therapeutics
  • Jason Brown (Scientific Director, Ubiquigent)
  • “Bio-Techne as a partner for the discovery and development of PROTACs”
  • Robert Felix (Head of Product Management, Tocris)
  • “A toolkit for PROTAC characterisation and monitoring the pathway to degradation”
  • Craig Malcolm (Promega)